Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-06-09
2009-11-10
Shukla, Ram R (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S145100, C530S387300, C530S388230
Reexamination Certificate
active
07615213
ABSTRACT:
This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5246701 (1993-09-01), Dugas et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5596072 (1997-01-01), Culpeper et al.
patent: 5599905 (1997-02-01), Mosley et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5652123 (1997-07-01), Caput et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5696234 (1997-12-01), Zurzwski et al.
patent: 5705154 (1998-01-01), Dalie et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5717072 (1998-02-01), Mosley et al.
patent: 5747037 (1998-05-01), Noelle et al.
patent: 5783181 (1998-07-01), Browne et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6140047 (2000-10-01), Duff et al.
patent: 6143871 (2000-11-01), Bonnefoy et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6214559 (2001-04-01), Collins et al.
patent: 6248714 (2001-06-01), Collins et al.
patent: 6268480 (2001-07-01), Collins et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6664227 (2003-12-01), Wynn et al.
patent: 6703360 (2004-03-01), McCall et al.
patent: 6746838 (2004-06-01), Choo et al.
patent: 6811780 (2004-11-01), Furfine et al.
patent: 6911530 (2005-06-01), Willson et al.
patent: 7078494 (2006-07-01), Collins et al.
patent: 7282206 (2007-10-01), Wynn et al.
patent: 2002/0136719 (2002-09-01), Shenoy et al.
patent: 2003/0013851 (2003-01-01), Powes et al.
patent: 2003/0023555 (2003-01-01), Rees
patent: 2003/0031666 (2003-02-01), Debinski et al.
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0166871 (2003-09-01), Barbas et al.
patent: 2003/0175898 (2003-09-01), Pantelidis
patent: 2003/0235555 (2003-12-01), Shealey et al.
patent: 2004/0023449 (2004-02-01), Hsu et al.
patent: 2004/0142372 (2004-07-01), McCall et al.
patent: 2004/0234499 (2004-11-01), Shealy et al.
patent: 2004/0248260 (2004-12-01), Heavner et al.
patent: 2005/0019260 (2005-01-01), Meeusen et al.
patent: 2005/0028496 (2005-02-01), Sabbadini et al.
patent: 2005/0032175 (2005-02-01), Stahl et al.
patent: 2005/0058645 (2005-03-01), Dunlop et al.
patent: 2005/0065327 (2005-03-01), Monk et al.
patent: 2005/0096268 (2005-05-01), Wynn et al.
patent: 2005/0142105 (2005-06-01), Puri et al.
patent: 2005/0154192 (2005-07-01), Shirakzwa et al.
patent: 2005/0164323 (2005-07-01), Chaudhary et al.
patent: 2005/0186146 (2005-08-01), Gong et al.
patent: 2005/0260216 (2005-11-01), Ashman et al.
patent: 2005/0266005 (2005-12-01), Heavner et al.
patent: 2005/0277126 (2005-12-01), Collins et al.
patent: 2005/0282216 (2005-12-01), Caput et al.
patent: 2006/0024306 (2006-02-01), Strober et al.
patent: 2006/0073148 (2006-04-01), Tchistiakova et al.
patent: 2007/0048785 (2007-03-01), Lin et al.
patent: 0 506 574 (1995-11-01), None
patent: 0812913 (1997-12-01), None
patent: 0 876 482 (1998-11-01), None
patent: 1 176 140 (2002-01-01), None
patent: 1 141 286 (2006-10-01), None
patent: WO 89/04838 (1989-06-01), None
patent: WO 91/09059 (1991-06-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 94/14975 (1994-07-01), None
patent: WO 95/14780 (1995-06-01), None
patent: WO 97/15663 (1997-05-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 97/29131 (1997-08-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/33913 (1997-09-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/30240 (1998-08-01), None
patent: WO 99/29888 (1999-06-01), None
patent: WO 00/36103 (2000-06-01), None
patent: 00/40264 (2000-07-01), None
patent: WO 00/64944 (2000-11-01), None
patent: WO 00/78336 (2000-12-01), None
patent: WO 01/23410 (2001-04-01), None
patent: WO 01/25282 (2001-04-01), None
patent: WO 01/62287 (2001-08-01), None
patent: 01/77332 (2001-10-01), None
patent: WO 01/92340 (2001-12-01), None
patent: WO 02/18445 (2002-03-01), None
patent: WO 02/055100 (2002-07-01), None
patent: WO 02/101629 (2002-12-01), None
patent: WO 03/034984 (2003-05-01), None
patent: WO 03/035847 (2003-05-01), None
patent: WO 03/086451 (2003-10-01), None
patent: 03/092610 (2003-11-01), None
patent: WO 04/001655 (2003-12-01), None
patent: WO 2004/039956 (2004-05-01), None
patent: WO 2004/047728 (2004-06-01), None
patent: WO 2004/069274 (2004-08-01), None
patent: WO 2005/007699 (2005-01-01), None
patent: WO 2005/009464 (2005-02-01), None
patent: WO 2005/016962 (2005-02-01), None
patent: WO 2005/019258 (2005-03-01), None
patent: WO 2005/042028 (2005-05-01), None
patent: WO 2005/062967 (2005-07-01), None
patent: WO 2005/062972 (2005-07-01), None
patent: WO 2005/079755 (2005-09-01), None
patent: WO 2005/081873 (2005-09-01), None
patent: WO 2005/091853 (2005-10-01), None
patent: WO 2005/091856 (2005-10-01), None
patent: WO 2005/121177 (2005-12-01), None
patent: WO 2006/003407 (2006-01-01), None
patent: WO 2006/085938 (2006-08-01), None
Eduardo Padlan, Mol Immunol. Feb. 1994;31(3):169-217.
Jefferies et al., Immunol Rev. Jun. 1998;163:59-76.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 94-105 (2001).
al Ghamdi et al., “IL-4 and IL-13 expression in chronic sinusitis: relationship with cellular infiltrate and effect of topical corticosteroid treatment,” J. Otolaryngol. 26:160-166 (1997).
Aversa et al., “An interleukin 4 mutant protein inhibits both IL-4 or IL-13 induced human immunoglobulin G4 and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors,” J. Exp. Med. 178:2213-18 (1993).
Bellanti, “Cytokines and allergic diseases: clinical aspects,” Allergy Asthma Proc. 19:337-341 (1998).
Blundell et al., “High-Throughput Crystallography for Lead Discovery in Drug Design,” Nature Reviews 11:45-54 (2002).
Bouma et al., “The Immunological and Genetic Basis of Inflammatory Bowel Disease,” Nature Reviews 3:521-532 (2003).
Casolaro et al., “Biology and genetics of atopic disease,” Curr. Opin. Immunol. 8:796-803 (1996).
Cocks et al., “IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand,” Int. Immunol. 5:657-663 (1993).
de Vries and Yssel, “Modulation of the human IgE response,” Eur. Respir. J. Suppl. 22:58s-62s (1996).
de Vries, “Novel fundamental approaches to intervening in IgE-mediated allergic diseases,” J. Invest. Dermatol. 102:141-144 (1994).
Doucet et al., “Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma,” J. Clin. Invest. 101:2129-39 (1998).
Gabrielsson et al., “Increased frequencies of allergen-induced interleukin-13-producing cells in atopic individuals during the pollen season,” Scand. J. Immunol. 48:429-35 (1998).
Ghaffar et al., “IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy,” Am. J. Respir. Cell. Mol. Biol. 17:17-24 (1997).
Gruenig et al., “Requirement of IL-13 independently of IL-4 in experimental asthma,” Science 282:2261-63 (1998).
Grunewald et al., “An antagonistic IL-4 mut
Donaldson Debra D.
Feyfant Eric
Fitz Lori J.
Goldman Samuel J.
Kasaian Marion T.
Lando & Anastasi LLP
Shukla Ram R
Skelding Zachary
Wyeth
LandOfFree
Antibodies against human interleukin-13 and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against human interleukin-13 and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against human interleukin-13 and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073479